Cross-Talk between modelling platforms: (B) application of the SBGN standard to a minimal PBPK model.




<u>Ben G Small</u>¹, Gaohua Lu¹, Sibylle Neuhoff¹, Kate Gill¹, Masoud Jamei¹, Geoffrey T Tucker¹, Trevor N Johnson¹, Maciej Swat³, Duncan Edwards¹, Amin Rostami-Hoedjgan^{1,2}
¹Simcyp-Certara, Blades Enterprise Centre, John Street, Sheffield, S2 4DN.
²School of Pharmacy, University of Manchester, Oxford Road, Manchester, M13 9PT.
³EMBL-European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SD.



Informal graphical model representation


 Despite their mathematical rigour, the diagrammatic representation of pharmacokinetic¹ (PK) and pharmacodynamic² (PD) models has largely been informal.



Use of the SBGN standard


 In a complementary abstract we detail the progress made in applying a set of standards within the Systems Biology community (SB).

 The systems biology graphical notation (SBGN)³ provides an existing standard that bridges understanding and unambiguously represents a



Methods

 A pre-existing model that was rendered within the Simcyp simulator^{4,5} was adopted and converted to an SBGN process description language level 1⁶ diagram using the Cell Designer (v 4.3) software⁷.



SBGN Process-Description language (level 1)⁶ diagram describing a minimal PBPK model of substrate (drug) absorption, distribution, metabolism and excretion within different tissues and physiological compartments. Compartments are represented as thickly-bordered container nodes. Source/Sink glyphs (i.e. red circle with a cross through it) represent the administration of a dose or the elimination of drug. Nodes are presented as either *entity pool nodes* – specifically macromolecules (i.e. drug) or as a process node (i.e. a square box) and connecting arc (i.e. line terminating in an arrow). Note that the drug nodes also have the *clone marker* attribute (i.e. a dark band across their base), this denotes multiple occurrences of this *entity pool node*. Italicised entries in this text refer to SBGN compliant nomenclature.

Labelling of dose, flows and clearances is non-compliant

Conclusion

- Adopting the SBGN standard can provide a semantically unambiguous and immediate understanding of a models utility and limitations. The use of software packages that 'write' the underlying SBML⁸ mark-up allow for the exchange of these models and the emerging PharmML⁹ standard aims to support SBML file import that would allow visualisation.
- Nevertheless, using entities or amounts (e.g. a drug / substrate) within PK models is challenging, as traditionally concentration (itself a derived parameter) is most often used.

Acknowledgments

*The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115156, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution. The DDMoRe project is also financially supported by contributions from Academic and SME partners."

References

Rowland Yeo K, *et al*. Eur J Pharm Sci. 2010;39(5):298-309.
Mager D *et al.* Drug Metab. Dispos. 2003; 31(5): 510-8.
Le Novère N, *et al.* Nat Biotechnol. 2009;27:735-41.
Jamei M, *et al.* In Silico Pharmacology. 2013;1:9.
Jamei M, *et al.* Exp Opin Drug Metab & Tox. 2009;5:211-23.

6.Moodie SL, *et al.* Nature Preceedings. 2011. 7.Funahashi A, *et al.* Proceedings of the IEEE. 2008;96:1254-65. 8.Hucka M, *et al.* Bioinformatics. 2003;19(4):524-31. 9.PharmML website: http://pharmml.org/